OS Therapies (OSTX) said Wednesday it received a US patent protecting its commercial manufacturing process for its listeria monocytogenes-based cancer immunotherapy platform through 2040.

The patent covers multiple assets, including lead candidate OST-HER2, which targets pediatric lung metastatic osteosarcoma and is expected to receive US Food and Drug Administration approval by the end of 2025, according to the company.

Other programs covered under the patent include OST-AXIL for HPV-related cancers, OST-503 for lung and brain cancers, OST-504 for prostate cancer, and eight pre-clinical immunotherapy candidates.

The patent also extends to OST-HER2's potential use in treating osteosarcoma in dogs.

OST-HER2 has received Rare Pediatric Disease designation from the FDA and may qualify for a $150 million Priority Review Voucher if granted conditional approval before September 2026, OS Therapies said.

Shares of OS Therapies were down nearly 8% in recent trading.

Price: 2.16, Change: -0.18, Percent Change: -7.74